1046317-48-9

Basic information

• Product Name: 4-[2-(4-benzofuran-2yl-phenylcarbamoyl)-2-(4-bromo-phenyl)-ethyl]-benzoic acid methyl ester
• Synonyms: 4-[2-(4-benzofuran-2yl-phenylcarbamoyl)-2-(4-bromo-phenyl)-ethyl]-benzoic acid methyl ester
• CAS NO: 1046317-48-9
• Molecular Weight: 554.44
• Mol File: 1046317-48-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[2-(4-benzofuran-2yl-phenylcarbamoyl)-2-(4-bromo-phenyl)-ethyl]-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(4-benzofuran-2yl-phenylcarbamoyl)-2-(4-bromo-phenyl)-ethyl]-benzoic acid methyl ester(1046317-48-9)
• EPA Substance Registry System: 4-[2-(4-benzofuran-2yl-phenylcarbamoyl)-2-(4-bromo-phenyl)-ethyl]-benzoic acid methyl ester(1046317-48-9)

Safety Data

• Hazardous Substances Data: 1046317-48-9(Hazardous Substances Data)

Upstream product

• 782-18-3 4-(benzofuran-2-yl)benzenamine 
• 1046320-79-9 C₁₇H₁₄BrClO₃ 

Relevant articles and documents

NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR

The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistence and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.